FINWIRES · TerminalLIVE
FINWIRES

Hong Kong Stocks Start Week Marginally Higher; Two Firms File to Go Public in Hong Kong

By

Hong Kong stocks began the week marginally higher as markets reacted to news of Iran and the U.S. reaching a preliminary deal to end hostilities and reopen the critical Strait of Hormuz.

The Hang Seng Index rose by around 124.57 points, or roughly 0.5%, to end at 24,842.67, while the Hang Seng China Enterprises Index finished near flat, inching up 1.31 points, or 0.02%.

U.S. President Donald Trump said on Truth Social on Monday that the deal with Iran would keep the Strait of Hormuz permanently open "toll-free" to shipping. He also authorized the immediate removal of the U.S. naval blockade from the key waterway.

In local development, Hong Kong's index of industrial production for manufacturing industries increased 3.1% year over year in the first quarter of 2026, but was below the 5.8% expansion recorded in the previous quarter.

By major sector, output volume was driven by a 6.6% rise in the metal, computer, electronic and optical products, machinery and equipment industry, while the food, beverages and tobacco sector grew by 2.1%.

Elsewhere, the Chamber of Hong Kong Listed Companies urged regulators to further ease listing requirements for innovative companies, saying that lower barriers would help attract more technology firms to raise capital in the city, the South China Morning Post reported, citing comments from its chairman, Chan Ka-keung.

In corporate news, two Chinese firms filed to go public in Hong Kong.

Shaanxi Micot Pharmaceutical Technology (HKG:2335) said it was seeking HK$1.22 billion via the sale of 58.1 million H shares at an indicative maximum price of HK$21.00 per share. The biotechnology firm is raising funds to advance clinical development of its drug candidates.

Meanwhile, Shanghai Seer Intelligent Technology (HKG:6106) is targeting as much as HK$1.07 billion with its offering of 10.5 million H shares at an indicative price of HK$101.60 per share. The robotics company will use proceeds to advance its technology and infrastructure.

Related Articles

Asia

Singapore Regulator to Streamline 'Single Family Office' Framework

The Monetary Authority of Singapore has revised its "single family office" (SFOs) framework to streamline the process for SFOs to establish operations in Singapore, according to a MAS release.An SFO in Singapore is a privately held corporate entity set up by one "ultra-high-net-worth" family to manage assets, investments, and wealth of a single family.The registration protocols have been simplified, effective June 15, with offices required to notify MAS of their operations through a MAS-licensed bank.Annual reporting has been made more straightforward for SFOs, with information on total assets under management and the name of its bank.

^STI
Asia

Klevo Rewards Plans Stablecoin Trial Launch by June 30; Shares Fall 4%

Klevo Rewards (ASX:KLV) said it plans to launch a trial of its KLVAUD Australian dollar-backed stablecoin by June 30, according to a Monday filing with the Australian bourse.The company's Fly Wallet subsidiary received legal advice indicating that the stablecoin may qualify as an eligible stablecoin under the current regulatory framework, subject to conditions, per the filing.KLVAUD is planned to be fully backed one-to-one by Australian dollars held in segregated reserve accounts, and aims to support Fly Wallet's broader payments system, the company said.Klevo Rewards shares fell 4% in recent Monday trade.

ASX:KLV
Asia

Bio-Thera Solutions Gets Europe's Results on On-Site Inspection

Bio-Thera Solutions (SHA:688177) received the results of the European Union's inspection of its Yonghe manufacturing facility, according to a Shanghai bourse filing on Monday.The French National Agency for the Safety of Medicines and Health Products conducted an inspection on the site between Feb. 4 and Feb. 12.The European Medicines Agency handed a GMP or good manufacturing practice certificate to the company after the factory's drug substance operations passed regulatory standards. However, the regulator found deficiencies in the deviation management measures for the finished formulation of the drugs.

SHA:688177